PT1450792E - Derivados de benzazole para o tratamento de esclerodermia - Google Patents

Derivados de benzazole para o tratamento de esclerodermia Download PDF

Info

Publication number
PT1450792E
PT1450792E PT02787919T PT02787919T PT1450792E PT 1450792 E PT1450792 E PT 1450792E PT 02787919 T PT02787919 T PT 02787919T PT 02787919 T PT02787919 T PT 02787919T PT 1450792 E PT1450792 E PT 1450792E
Authority
PT
Portugal
Prior art keywords
quot
alkyl
group
scleroderma
aryl
Prior art date
Application number
PT02787919T
Other languages
English (en)
Portuguese (pt)
Inventor
Jean-Pierre Gotteland
Pascale Gaillard
Yolande Chvatchko
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of PT1450792E publication Critical patent/PT1450792E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02787919T 2001-12-07 2002-12-06 Derivados de benzazole para o tratamento de esclerodermia PT1450792E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01000727 2001-12-07

Publications (1)

Publication Number Publication Date
PT1450792E true PT1450792E (pt) 2006-12-29

Family

ID=8176107

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02787919T PT1450792E (pt) 2001-12-07 2002-12-06 Derivados de benzazole para o tratamento de esclerodermia

Country Status (13)

Country Link
US (1) US7776854B2 (cg-RX-API-DMAC7.html)
EP (1) EP1450792B1 (cg-RX-API-DMAC7.html)
JP (2) JP4589002B2 (cg-RX-API-DMAC7.html)
AT (1) ATE340572T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002352227B2 (cg-RX-API-DMAC7.html)
CA (1) CA2468826C (cg-RX-API-DMAC7.html)
DE (1) DE60215042T2 (cg-RX-API-DMAC7.html)
DK (1) DK1450792T3 (cg-RX-API-DMAC7.html)
ES (1) ES2268127T3 (cg-RX-API-DMAC7.html)
IL (1) IL162259A0 (cg-RX-API-DMAC7.html)
PT (1) PT1450792E (cg-RX-API-DMAC7.html)
SI (1) SI1450792T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003047570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20070527T3 (en) * 2003-09-12 2007-12-31 Laboratoires Serono Sa Benzothiazole derivatives for the treatment of diabetes
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US20070203134A1 (en) * 2004-09-10 2007-08-30 Applied Research Systems Ars Holding N.V. Benzimidazole Acetonitriles
JP5144271B2 (ja) * 2004-11-17 2013-02-13 アレス トレーディング ソシエテ アノニム ベンゾチアゾ−ル製剤、及びそれらの使用
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 jnk 억제제
EP2026802A2 (en) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk inhibitors for treatment of skin diseases
US20080305186A1 (en) * 2007-06-11 2008-12-11 Board Of Regents, The University Of Texas System Method and Composition for the Treatment of Cardiac Hypertrophy
AU2009246333B2 (en) * 2008-05-16 2013-05-09 Corthera, Inc. Method of promoting wound healing
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0666812B2 (ja) * 1988-01-11 1994-08-24 日本電気株式会社 パケット交換方法並びにパケット交換装置
US5985592A (en) 1997-06-05 1999-11-16 Dalhousie University Uses for pentoxifylline or functional derivatives/metabolites thereof
WO2000075118A1 (en) * 1999-06-03 2000-12-14 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK)
EP1110957A1 (en) 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
CA2430539C (en) * 2000-12-05 2010-07-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
AU2002352227B2 (en) 2007-11-01
EP1450792B1 (en) 2006-09-27
ES2268127T3 (es) 2007-03-16
JP4589002B2 (ja) 2010-12-01
EP1450792A1 (en) 2004-09-01
US7776854B2 (en) 2010-08-17
CA2468826A1 (en) 2003-06-12
WO2003047570A1 (en) 2003-06-12
DE60215042T2 (de) 2007-10-04
SI1450792T1 (sl) 2006-12-31
JP2010248205A (ja) 2010-11-04
DK1450792T3 (da) 2007-01-29
CA2468826C (en) 2011-11-01
IL162259A0 (en) 2005-11-20
ATE340572T1 (de) 2006-10-15
JP2005515994A (ja) 2005-06-02
DE60215042D1 (de) 2006-11-09
AU2002352227A1 (en) 2003-06-17
US20050119277A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
JP2010248205A (ja) 強皮症の治療のためのベンザゾール誘導体
ES2818977T3 (es) Método para obtener cristales de sal de meglumina de ácido 1-(5,6-dicloro-1H-benzo[d]imidazol-2-il)-1H-pirazol-4-carboxílico
US20060281749A1 (en) Method for treating glaucoma IV B
ES2975235T3 (es) Hidantoínas que modulan el procesamiento de APP mediado por BACE
EP1746099A1 (en) Mnk1 or Mnk2 inhibitors
BRPI0620463A2 (pt) composição farmacêutica oftálmica, compostos, e seus usos
JPWO2007083689A1 (ja) プラスミノーゲンアクチベーターインヒビター−1阻害剤
PT91597B (pt) Processo para tratar lesoes cutaneas usando antagonistas do receptor de tromboxano a2 como o 7-oxabiciclo-{2.2.1}hept-2-1}5-heptenoico
PT1696909E (pt) Derivados benzotiazolo para o tratamento de diabetes
CN105985295B (zh) 一种旋光纯的硫代乙酸类化合物
PT622077E (pt) Antagonistas da angiotensina ii como farmacos profilacticos ou terapeuticos para doencas renais
CN107206002B (zh) 尿酸性或痛风性疾病的预防或治疗
KR20220127826A (ko) 화합물 및 α1-항트립신 결핍의 치료를 위한 이의 용도
JPH04211020A (ja) トロンボキサンシンセターゼ阻害剤および/またはトロンボキサンレセプター拮抗剤またはそれらの組合せを用いて血清尿酸を減少させそして/または直腸の尿酸クリアランスを増加させる方法
KR20100135953A (ko) 안 질환 치료를 위한 pai―1 발현 및 활성 억제제
JPWO1999040919A1 (ja) 心拡張障害治療剤
KR20010040837A (ko) 확장기(擴張期) 기능장애 치료용 의약
WO1998051313A1 (fr) Remedes contre les yeux secs
JP5559696B2 (ja) 糖尿病性腎症の治療剤
BRPI0710122A2 (pt) inibidores de preniltransferase para controle de hipertensão ocular e tratamento de glaucoma
WO2024163892A9 (en) Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
CN117224546A (zh) Cz415在制备降眼压药物上的应用
US20100016358A1 (en) Gamma-globin inducer
US20190231751A1 (en) Treatment of fibrotic disorders with jun n-terminal kinase inhibitors
JPH09316002A (ja) 眼疾患用薬剤